Combining Immunotherapy for Kidney Cancer
The FDA has approved a combination of ipilimumab and nivolumab for treating intermediate- or poor-risk, previously untreated advanced renal...
Progress Against Cancer
The FDA has approved a combination of ipilimumab and nivolumab for treating intermediate- or poor-risk, previously untreated advanced renal...
An FDA-approved precision medicine treatment is for certain patients with metastatic lung cancer with a specific BRAF mutation. The...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
A new hormone therapy is the first treatment to be approved because it was found to markedly delay the...
The FDA has expanded the use of a molecularly targeted therapeutic to include patients with multiple myeloma. The U.S....
The FDA has approved the molecularly targeted therapeutic olaparib for treating patients who have HER2-negative breast cancer and who...
The FDA has expanded the use of a CD30-targeted antibody?drug conjugate to include two additional types of lymphoma. The...
The newly approved therapeutic is for certain patients with an aggressive type of non-Hodgkin lymphoma called mantle cell lymphoma....
The second of a groundbreaking new type of immunotherapy called CAR T-cell therapy is approved for certain types of...
The FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of...